Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome.
Melchert
M
M
Williams
C
C
List
A
A
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics; D012074:Remission Induction / Q000379:methods; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide